# Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

> **NCT04718038** · — · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 60 (actual)

## Conditions studied

- Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab combind mFOLFOX6/FOLFIRI

## Key facts

- **NCT ID:** NCT04718038
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2018-02-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718038, "Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04718038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*